[1] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰 竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊 断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789. [2] Husedzinovic I, Husedzinovic S, Milanovic R. Levosimen-dan in acute heart failure [J]. Signa Vitae,2009,3(Suppl 1): S13-16. [3] García- González MJ, Jorge- Pérez P, Jiménez- Sosa A, et al. Levosimendan improves hemodynamic status in criti-cally ill patients with severe aortic stenosis and left ventric-ular dysfunction: an interventional study [J]. Cardiovasc Ther,2015,33(4):193-199. [4] De Hert SG, Wikstr?m BG, Meyer S,et al. Levosimen-dan: molecular mechanisms and clinical implications [J]. Int J Cardiol, 2011,215:26-31. [5] Jia Z, Guo M, Zhang YQ, et al. Efficacy of intravenous levosimendan in patients with heart failure complicated by acute myocardial infarction [J]. Cardiol,2014,128(2):195-201. [6] Pollesello P, Parissis J, Kivikko M,et al. Levosimendan meta-analyses: is there a pattern in the effect on mortality [J]. Int J Cardiol, 2016,209:77-83. [7] Belletti A, Castro ML, Silvetti S,et al. The Effect of in-otropes and vasopressors on mortality: a meta-analysis of randomized clinical trials [J]. Br J Anaesth, 2015,115(5): 656-675. [8] 杜贺,史承勇.左西孟旦的研究新进展[J].中国循环杂志,2014,29 (7):555-557. [9] de Lissovoy G, Fraeman K, Teerlink JR, et al. Hospital costs for treatment of acute heart failure: economic analysisof the REVIVE Ⅱstudy [J]. Eur J Health Econ, 2010,11 (2):185-193. [10] Crespo-Leiro MG, Metra M, Lund LH,et al. Advanced heart failure: a position statement of the Heart Failure As-sociation of the European Society of Cardiology [J]. Eur J Heart Fail,2018,71:129-136. [11] Frommeyer G, Kohnke A, Ellermann C,et al. Acute in-fusion of levosimendan enhances atrial fibrillation in an ex-perimental whole-heart model [J]. Int J Cardiol, 2017,236: 423-426. [12] Frommeyer G, Kohnke A, Ellermann C, et al. Experi-mental evidence for a severe proarrhythmic potential of le-vosimendan [J]. Int J Cardiol,2017,228:583-587. [13] 蒋铂.rhBNP对体外循环病人TNF-α和IL-10的影响[D].中南 大学,2010. [14] 吴金波,王雁娟,李明秋,等.重组人脑利钠肽对体外循环下心脏 手术术后肾功能的影响[J].临床麻醉学杂志,2011,27(3):264-266. [15] 张丛雅,王古岩.重组人脑利钠肽在心脏外科中的脏器保护作用 [J].中国分子心脏病学杂志,2017,17(5):2259-2261. [16] 林国强,罗万俊,李迎秋,等.重组人脑利钠肽对体外循环心脏瓣 膜置换术患者血浆内毒素及全身炎性反应的影响[J].中华胸心血 管外科杂志,2012,28(5):294-297. [17] 潘洁丽,郏国炯,王萌.老年急性心肌梗死患者在冠状动脉介入术 后采用重组人脑利钠肽治疗的应用价值[J].心肺血管病杂志, 2018,37(11):972-975. [18] 重组人脑利钠肽多中心研究协作组.重组人脑利钠肽治疗心力衰 竭安全性和疗效的开放性随机对照多中心临床研究[J].中华心血 管病杂志,2011,39(4):305-308. [19] 巫菲,稂与恒,米睿,等.急性心肌梗死急诊PCI术后早期应用新 活素疗效的Meta分析[J].中国循证心血管医学杂志,2016,8(6): 672-675. [20] 刘斌.新活素、左西孟旦和托伐普坦联合应用治疗顽固性心力衰 竭疗效观察[J].国际心血管病杂志,2015,42(6):431-432. [21] 陈宏志,李静蔚,何建成.基于临床病案文献的帕金森病中医基本 证候研究[J].中华中医药杂志,2016,63(8):3216-3219. [22] 李一青.米力农联合多巴胺在老年顽固性心力衰竭中的临床效果 [J].临床医学研究与实践,2017,2(15):17-18. [23] 谢传洪.米力农联合多巴胺在老年顽固性心力衰竭治疗中的应用 价值分析[J].中国医药科学,2016,6(8):56-58.